首页 > 市场调查报告书 > 製药

血友病市场规模、份额和成长分析（按类型、产品、疗法、治疗方法和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1897172

血友病市场规模、份额和成长分析（按类型、产品、疗法、治疗方法和地区划分）—2026-2033年产业预测

Hemophilia Market Size, Share, and Growth Analysis, By Type, By Product, By Therapy, By Treatment, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，血友病市场规模将达到 143.9 亿美元，到 2025 年将达到 153.4 亿美元，到 2033 年将达到 255.8 亿美元，在预测期（2026-2033 年）内，复合年增长率为 6.6%。

血友病市场正经历强劲成长，这主要得益于基因疗法的近期核准以及众多处于不同研发阶段的候选药物。民众对血友病的认知度不断提高，以及政府为促进新生儿早期筛检所采取的倡议，进一步推动了市场扩张。血友病是一种性连锁遗传疾病，主要影响男性，这导致其盛行率较高。全球调查显示，血友病患者群体庞大，其中相当一部分患者被诊断为血友病A、B和非特异性血友病。如此高的盛行率直接促使更多人接受治疗方法，从而进一步推动了市场发展。随着相关人员致力于创新疗法，血友病领域可望持续发展壮大。

血友病市场驱动因素

血友病市场的主要驱动力是基因疗法、重组凝血因子浓缩物和个人化医疗等治疗方法的显着进步。这些创新治疗方法正在改变血友病的治疗方式，显着改善患者的治疗效果，并大幅提升他们的生活品质。随着新的治疗方案不断涌现，不仅治疗效果更加显着，患者还能获得更个人化的解决方案，满足其个别需求，最终推动血友病市场的发展和演变，因为医疗服务提供者正努力提供最佳的医疗服务。

血友病市场限制因素

由于治疗费用高昂，尤其是基因疗法等创新治疗方法的高成本，血友病市场面临巨大的限制。这些经济负担严重阻碍了患者寻求有效治疗，并常常限制了他们获得先进治疗方案的机会。医疗系统也可能因提供这些先进疗法而承受沉重的经济负担。血友病市场固有的经济挑战有可能影响患者的治疗效果，并阻碍治疗领域的整体进展，因此亟需更经济实惠的解决方案，以改善有需要人群的医疗服务。

血友病市场趋势

血友病领域的一个显着市场趋势是基因疗法的日益普及。这种治疗方法有望透过靶向疾病的潜在遗传问题，彻底改变治疗模式。这种创新方法旨在引入功能性基因，使患者能够合成必需的凝血因子，从而显着改善其生活品质。病毒载体技术的进步和对基因操作更深入的理解推动了基因疗法的发展。大量临床试验已显示出令人鼓舞的结果，表明基因疗法可能提供一种持久的解决方案，并减少对传统因子替代疗法的持续依赖。这正在重塑血友病的治疗模式。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Bayer AG（Germany）
BioMarin Pharmaceutical Inc.（United States）
CSL Behring（Australia）
Kedrion（Italy）
Novo Nordisk（Denmark）
Pfizer Inc.（United States）
Roche（Chugai Pharmaceutical Co.）（Switzerland/Japan）
Sanofi（Genzyme Corporation）（France/United States）
Takeda Pharmaceutical（Shire Plc.）（Japan/Ireland）
Grifols（Spain）
Octapharma（Switzerland）
F. Hoffmann-La Roche Ltd（Switzerland）
Biogen（United States）
Baxalta（United States）
LFB Group（France）
Bioverativ Inc.（United States）
Bio Products Laboratory Ltd.（United Kingdom）
Kogenate（Germany）
Sangamo Therapeutics, Inc.（United States）

结论与建议

简介目录

Product Code: SQMIG35D2191

Hemophilia Market size was valued at USD 14.39 Billion in 2024 and is poised to grow from USD 15.34 Billion in 2025 to USD 25.58 Billion by 2033, growing at a CAGR of 6.6% during the forecast period (2026-2033).

The hemophilia treatment market is experiencing robust growth fueled by the recent approvals of gene therapies and a wealth of candidates in various stages of development. Enhanced awareness of hemophilia, coupled with government initiatives promoting early detection in newborns, further bolsters market expansion. The disorder predominantly affects males due to its sex-linked nature, contributing to its prevalence. Global surveys reveal a significant patient population, with many individuals diagnosed with types A, B, and unspecified hemophilia. This high prevalence is directly influencing the rising adoption of therapies, reinforcing the market's momentum. As stakeholders focus on innovative treatment solutions, the hemophilia landscape is poised for continued evolution and growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemophilia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemophilia Market Segments Analysis

Global Hemophilia Market is segmented by Type, Product, Therapy, Treatment and region. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, Hemophilia C and Others. Based on Product, the market is segmented into Plasma derived coagulation factor concentrates, Recombinant coagulation factor concentrates and Desmopressin and antifibrinolytic agents. Based on Therapy, the market is segmented into On-demand and Prophylaxis. Based on Treatment, the market is segmented into Replacement therapy, ITI therapy and Gene Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemophilia Market

The hemophilia market is primarily driven by significant advancements in treatment approaches, including gene therapy, recombinant factor concentrates, and personalized medicine. These innovative therapies have transformed the management of hemophilia, leading to better patient outcomes and a marked improvement in overall quality of life for those affected by the disorder. As new treatment options continue to emerge, they not only enhance the efficacy of care but also offer patients more tailored solutions that meet their individual needs, ultimately contributing to the growth and evolution of the hemophilia market as healthcare providers seek to deliver optimal care.

Restraints in the Hemophilia Market

The hemophilia market faces significant constraints due to the high costs associated with treatments, especially innovative therapies like gene therapy. These financial burdens can create substantial obstacles for patients seeking effective care, often limiting their access to advanced therapeutic options. Healthcare systems may also experience strain as they navigate the expenses related to providing these sophisticated treatments. The economic challenges inherent in the hemophilia market can impede patient outcomes and hinder the overall progress of therapeutic advancements, emphasizing the need for more affordable solutions to enhance accessibility for individuals requiring care.

Market Trends of the Hemophilia Market

A prominent market trend in the hemophilia sector is the increasing integration of gene therapy, which is poised to transform treatment paradigms by targeting the root genetic issues of the disorder. This innovative approach aims to deliver functional genes that enable patients to synthesize essential clotting factors, significantly enhancing their quality of life. The rise of gene therapy is fueled by advancements in viral vector methodologies and a deeper comprehension of genetic manipulation. Numerous clinical trials have reported encouraging outcomes, indicating that gene therapy could offer enduring solutions and alleviate the ongoing need for conventional factor replacement therapies, thereby reshaping the treatment landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Hemophilia Market Size by Type & CAGR (2026-2033)

Market Overview
Hemophilia A
Hemophilia B
Hemophilia C
Others

Global Hemophilia Market Size by Product & CAGR (2026-2033)

Market Overview
Plasma derived coagulation factor concentrates
Recombinant coagulation factor concentrates
Desmopressin and antifibrinolytic agents

Global Hemophilia Market Size by Therapy & CAGR (2026-2033)

Market Overview
On-demand
Prophylaxis

Global Hemophilia Market Size by Treatment & CAGR (2026-2033)

Market Overview
Replacement therapy
ITI therapy
Gene Therapy

Global Hemophilia Market Size & CAGR (2026-2033)

North America (Type, Product, Therapy, Treatment)
- US
- Canada
Europe (Type, Product, Therapy, Treatment)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Product, Therapy, Treatment)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Product, Therapy, Treatment)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Product, Therapy, Treatment)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (Genzyme Corporation) (France/United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxalta (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioverativ Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Products Laboratory Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kogenate (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments